Abstract. The clinical use of doxorubicin (DOX), a potent antineoplastic agent, is limited by its serious side-effects, which include acute and chronic cumulative dose-related cardiotoxicity. Berberine (BER), a botanical alkaloid, has been reported to possess cardioprotective and antitumor effects. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazolium bromide (MTT) assay was used to detect the cell viability of A549, HeLa and HepG2 cells after each cell line was treated with DOX, BER or a combination of DOX and BER for 24 h. Apoptosis was evaluated by acridine orange staining. The results showed that BER and DOX exhibited dose-dependent inhibitory effects on A549 and HeLa cells which were likely mediated by inducing apoptosis. The same result was found in the combination group. Isobologram illustration and combination index (CI) analyses revealed that the combination of DOX and BER generates synergistic effects in A549 (CI=0.61) and HeLa (CI= 0.73) cells. These findings indicate that BER sensitizes cells to the anticancer effects of DOX.
Introduction
Doxorubicin (DOX), an anthracycline antibiotic and antineoplastic agent, was first isolated from Streptomyces peucetius (1) . DOX is a potent chemotherapeutic agent that is used in the treatment of solid tumors and malignant hematological diseases (2) . DOX exerts its antitumor activity by inserting into DNA, leading to double-stranded DNA breaks (DSB), and intercepting DNA topoisomerase II activity (3, 4) . However, the clinical use of DOX has been largely restricted due to its cardiotoxicity, which may lead to the development of cardiomyopathy and ultimately congestive heart failure (5). The molecular mechanisms underlying DOX-induced cardiotoxicity include the formation of free radicals, activation of transcription factor NF-κB, increased lipid peroxidation and Ca 2+ overloading (6) (7) (8) . The use of cardioprotective drugs is an alternative approach to reduce the cardiotoxicity of DOX. Pharmacological and clinical attempts to reduce the cardiotoxicity of DOX have had little success thus far. Consequently, it is important to develop a therapy to reduce DOX-induced cardiotoxicity and increase the antitumor effect of DOX.
Berberine (BER), a botanical alkaloid, is purified from the roots and bark of the Berberis species (9) . BER reportedly possesses multiple biological and pharmacological properties, including anti-diarrheal, anti-fungal, anti-diabetic (10-12), hepatoprotective and cardioprotective effects. The possible mechanism of the hepatoprotective effect is that BER inhibits the activity of CYP 2E1 and CYP 1A2, reduces the production of nitric oxide and lowers the AST and ALT levels in serum (13, 14) . For the cardioprotective property, BER is known to modulate Cdk9 and cyclin T1 protein expression. BER possesses muscarinic agonist-like properties which may contribute to a reduction in myocardial damage (15) (16) (17) . BER also suppresses tumor growth through the induction of apoptosis and cell cycle arrest in cancer cells (18) (19) (20) (21) . Notably, it has been reported that the acute toxicity of BER was not observed at normal dosage in mice (22) .
Based on these findings, we hypothesized that combining DOX with BER as a novel strategy for tumor therapy would not only increase the effect of DOX, but also prevent the cardiotoxicity induced by DOX. The present study was therefore performed to test this hypothesis in A549, HepG2 and HeLa cells. Our observations revealed that BER enhances the antitumor effects of DOX in A549 and HeLa cells. (Fig. 1) . As shown in Fig. 1, 100 Table IB . A549 and HeLa cells were found to be more sensitive to BER than HepG2 cells (Table I ). A549 cells were the most sensitive to DOX. In the present study, we found that the IC 50 of the combination of BER and DOX was lower than that of each drug used alone.
Materials and methods

Chemicals
Synergistic action of BER and DOX.
Isobolograms were used to evaluate whether combining BER and DOX generates a synergistic effect (24) . As shown in Fig. 2 , the Y-axis shows the IC 50 of BER and the X-axis shows the IC 50 of DOX. The straight line (additivity line) connects the IC 50 values of DOX and BER when the drugs are used alone. In the present study, we found that the IC 50 of combined DOX and BER was below the straight line, indicating that a combination of the two drugs may generate a synergistic antitumor effect in A549 and HeLa cells (Fig. 2) 
Combined treatment with BER and DOX causes solid tumor cell apoptosis.
To assess whether the decrease in viability was mediated by inducing apoptosis, cells that had been treated with the two drugs were stained with AO. Results showed that the single and combined treatment with DOX and BER induced apoptosis (Fig. 3) . The number of apoptotic cells was increased in the combination group compared with the single treatment group (Fig. 3D) , suggesting that the combination of DOX and BER synergistically induces the apoptosis of A549 cells.
Discussion
The findings of the present study indicate that BER, a botanical alkaloid, is able to enhance the anticancer effect of DOX in A549 and HeLa cells. Our results have shown that DOX and BER significantly reduced the viability of A549 and HeLa cells. From the IC 50 of DOX and BER, we found that the IC 50 of the combination of DOX and BER was lower than the IC 50 of the drugs used singly. Notably, the results of this study demonstrate that combining DOX with BER generates a synergistic anticancer effect in A549 and HeLa cells.
DOX has been found to have anticancer activities against a range of solid tumors. However, the therapeutic use of DOX has been limited by its serious dose-related cardiotoxicity (25) . BER has been reported to be safe and beneficial in the treatment of patients with chronic congestive heart failure (16) . Therefore, combining DOX with BER is a novel strategy for the treatment of cancer and reduction of the cardiotoxicity induced by DOX.
BER is a naturally occurring botanical alkaloid that is found in the roots and bark of the Berberis species. In clinical use, BER possesses anti-inflammatory, anti-diarrheal and anti-fungal effects. BER has also been reported to possess anticancer properties and anti-metastatic effects in non-small cell lung cancer A549 cells (26) . The mechanism of its antitumor effect is that BER induces apoptosis and cell cycle arrest in cancer cells (27, 28) . However, the anticancer effect of BER is 
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associated with the cell type; the IC 50 of BER in the HepG2 cell line is 3,587.8 µM, which is extremely high for an antitumor drug, but the IC 50 of BER is lower in A549 and HeLa cells. Our results have shown that BER induces apoptosis in A549 cells. Notably, the combination of DOX and BER also synergistically induced the apoptosis of A549 cells (Fig. 3) . These data suggest that the induction of apoptosis is the mechanism by which the combination of DOX and BER inhibits the growth of A549 cells. However, more investigations are required to demonstrate the efficacy of the combination of DOX and BER in treating cancer patients.
The induction of apoptosis is one of the antitumor mechanisms of DOX and BER. This is in accordance with the theory of ʻindependent similar actionʼ (29) . Therefore, combining DOX with BER may achieve a synergistic antitumor effect. In the present study, we used isobologram illustrations to detect (Fig. 3) . Thus, more studies should be conducted to detect the mechanism of the synergistic anticancer action of DOX and BER.
In conclusion, we confirmed that the combination of DOX and BER synergistically generates anticancer effects in A549 and HeLa cells in vitro, possibly mediated by inducing apoptosis. With regard to HepG2 cells, the IC 50 of BER is extremely high for an antitumor agent. The combination of DOX with BER is a novel strategy that has potential in the treatment of cancer patients.
